Your browser doesn't support javascript.
loading
Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
Ara, R; Pandor, A; Stevens, J; Rafia, R; Ward, S E; Rees, A; Durrington, P N; Reynolds, T M; Wierzbicki, A S; Stevenson, M.
Affiliation
  • Ara R; School of Health & Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, UK. r.m.ara@sheffield.ac.uk
Eur J Prev Cardiol ; 19(3): 474-83, 2012 Jun.
Article in En | MEDLINE | ID: mdl-21460076
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Drugs, Generic / Drug Costs / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Secondary Prevention Type of study: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Eur J Prev Cardiol Year: 2012 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Drugs, Generic / Drug Costs / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Secondary Prevention Type of study: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Eur J Prev Cardiol Year: 2012 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom